R74
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 138
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.340
- HEDGEHOG_SIGNALING+0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- OXIDATIVE_PHOSPHORYLATION+0.250
- INFLAMMATORY_RESPONSE+0.240
- NOTCH_SIGNALING+0.240
- PEROXISOME+0.240
- XENOBIOTIC_METABOLISM+0.240
- ADIPOGENESIS+0.220
- APICAL_JUNCTION+0.220
Top 10 suppressed
- PROTEIN_SECRETION-0.430
- ANGIOGENESIS-0.180
- UV_RESPONSE_DN-0.160
- PANCREAS_BETA_CELLS-0.150
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.140
- TGF_BETA_SIGNALING-0.140
- E2F_TARGETS-0.130
- G2M_CHECKPOINT-0.090
- PI3K_AKT_MTOR_SIGNALING-0.090
- SPERMATOGENESIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG413 | — | — | 0.748 |
| 2 | 131e315e-6653-4199-b653-42b81644dad9 | — | — | 0.734 |
| 3 | R228 | — | — | 0.723 |
| 4 | MNG610 | — | — | 0.707 |
| 5 | SRR4296092 | — | cohortA1 | 0.698 |
| 6 | d6b7de60-321d-4f6d-82e7-3d5e9598462c | — | — | 0.691 |
| 7 | b83a1cf6-50a6-44fa-834d-8b3df88149fa | — | — | 0.685 |
| 8 | SRR33346940 | — | — | 0.685 |
| 9 | SRR10842364 | — | — | 0.680 |
| 10 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.678 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |